# LINEAGE CELL THERAPEUTICS IN (LCTX)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/LCTX/

- Reporting holders: 5
- Reported value: $6.4M
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Defender Capital, LLC.](https://holderbook.com/funds/1766929-defender-capital-llc/) | $6.4M | 6,648,899 | 2.0% | 4 |
| [CHAPIN DAVIS, INC.](https://holderbook.com/funds/872098-chapin-davis-inc/) | $19.1K | 20,000 | 0.0% | 7 |
| [Pacifica Partners Inc.](https://holderbook.com/funds/1799900-pacifica-partners-inc/) | $2.6K | 2,926 | 0.0% | 28 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $2.2K | 2,273 | 0.0% | 1 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $1.1K | 1,126 | 0.0% | 7 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 5 | $6.4M |
| Q2 2026 | 135 | $157.4M |
| Q1 2026 | 129 | $176.8M |
| Q4 2025 | 121 | $170.1M |
| Q3 2025 | 112 | $149.3M |
| Q2 2025 | 130 | $89.3M |
| Q1 2025 | 128 | $49.8M |
| Q4 2024 | 124 | $53.9M |
| Q3 2024 | 113 | $86.3M |
| Q2 2024 | 113 | $99.6M |
| Q1 2024 | 115 | $140.9M |
| Q4 2023 | 115 | $83.9M |